
Phyteau
@phyteau
Developing a completely safe, new class of therapeutics for diabetes, obesity, NAFLD & related metabolic conditions. Startup. RebelBio 2017. Plug and Play 2019
ID: 25680016
http://www.phyteau.co/ 21-03-2009 14:39:40
627 Tweet
1,1K Followers
2,2K Following








#WeightLoss Not Enough to Sustain #Type2Diabetes Remission "Among more than 37,000 people with #T2D in Hong Kong, only 6% had achieved and sustained #diabetes remission solely through weight loss up to 8 years after diagnosis." medscape.com/viewarticle/we⦠medscape.com/viewarticle/weā¦





Study: Prevalence of #Diabetes Expected to Increase by 59.7% in 2025 - #obesity main risk factor. pharmacytimes.com/view/study-pre⦠Pharmacy Times #T2D #bloodsugar #Type2Diabetes


American Diabetes Association advises against Compounded GLP 1 and Dual GIP/GLP 1 Receptor Agonists drugs. Full Statement here: diabetesjournals.org/care/article/d⦠American Diabetes Association - DiabetesPro #Diabetes #GLP1 #T2D #obesity #weightloss American Diabetes Association #ADA



